
@article {43847,
	title = {Does retinoic acid reverse cell cycle dysregulation in Alzheimer{\textquoteright}s disease lymphocytes?},
	journal = {Asian J Psychiatr},
	volume = {39},
	year = {2019},
	month = {2018 Aug 16},
	pages = {174-177},
	abstract = {<p>Aberrant re-entry of neurons into cell cycle appears to be an early event in Alzheimer{\textquoteright}s disease (AD) and targeting this dysregulation may have therapeutic potential. We have examined whether cell cycle dysregulation in AD can be detected using patient and control derived B-lymphocytes. Cell cycle analysis using flow cytometry demonstrated that cell cycle dysregulation occurs in AD lymphocytes, with a significant difference in the distribution of cells in G0/G1, S and G2/M phases of cell cycle as compared to control lymphocytes. Using global gene expression analysis by RNA sequencing and cell cycle analysis, we examined the role of Retinoic Acid (RA), a candidate molecule predicted to be of therapeutic potential in cell cycle dysregulation associated with AD. CCND1, CCNE2, E2F transcription factors which are known to be dysregulated in AD were among the 32 genes that showed differential expression in response to RA treatment thus suggesting a protective role of RA. However, the cell cycle analysis demonstrated that RA did not reverse the cellular phenotype in AD lymphocytes. This suggests that though RA might have a protective role by influencing the expression of cell cycle genes, it might not be able to arrest abnormal re-entry into cell cycle.</p>
},
	issn = {1876-2026},
	doi = {10.1016/j.ajp.2018.08.010},
	author = {Ashok, Aparna and Naaz, Safoora and Kota, Lakshmi Narayanan and Sen, Somdatta and Purushottam, Meera and Faruq, Mohammed and Kumari, Renu and Yadav, Vinod and Kannan, Ramakrishnan and Jain, Sanjeev and Panicker, Mitradas M and Viswanath, Biju}
}
@article {49143,
	title = {Derivation of iPSC lines from two patients with familial Alzheimer{\textquoteright}s disease from India.},
	journal = {Stem Cell Res},
	volume = {34},
	year = {2018},
	month = {2018 Dec 19},
	pages = {101370},
	abstract = {<p>The current prevalence of diagnosable dementia in India is 1\% of people over 60 years (~3.7 million people), but is estimated to increase significantly, as ~15\% world{\textquoteright}s aged population (\&gt;65 years) would be resident here by 2020 (Shah et al., 2016). While several mutations that pose a familial risk have been identified, the ethnic background may influence disease susceptibility, clinical presentation and treatment response. In this study, we report a detailed characterization of two representative HiPSC lines from a well-characterized dementia cohort from India. Availability of these lines, and associated molecular and clinical information, would be useful in the detailed exploration of the genomic contribution(s) to AD.</p>
},
	issn = {1876-7753},
	doi = {10.1016/j.scr.2018.101370},
	author = {Najar, Ashaq H and Sneha, K M and Ashok, Aparna and Babu, Swathy and Subramaniam, Anand G and Kannan, Ramkrishnan and Viswanath, Biju and Purushottam, Meera and Varghese, Mathew and Parvez, Suhel and Panicker, Mitradas M and Mukherjee, Odity and Jain, Sanjeev}
}
